On the contrary, no significant effect was noted when other ICAM-1 ligands (CD11b and CD11c) were blocked on tumor cells by neutralizing antibodies or when the ligand for the β1 integrin VLA-4, VCAM-1, was neutralized on LSECs (light grey, Fig. 3c). Here, ITGAX is linked to neoplasm.